These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 16845661)
1. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Lee L; Sudentas P; Dabora SL Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690 [TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. Messina MP; Rauktys A; Lee L; Dabora SL BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349 [TBL] [Abstract][Full Text] [Related]
4. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729 [TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Kwiatkowski DJ; Manning BD Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in neurobiology of Tuberous Sclerosis Complex. Napolioni V; Moavero R; Curatolo P Brain Dev; 2009 Feb; 31(2):104-13. PubMed ID: 19028034 [TBL] [Abstract][Full Text] [Related]
7. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366 [TBL] [Abstract][Full Text] [Related]
8. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Kenerson H; Dundon TA; Yeung RS Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109 [TBL] [Abstract][Full Text] [Related]
9. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. El-Hashemite N; Zhang H; Walker V; Hoffmeister KM; Kwiatkowski DJ Cancer Res; 2004 May; 64(10):3436-43. PubMed ID: 15150095 [TBL] [Abstract][Full Text] [Related]
10. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. Woodrum C; Nobil A; Dabora SL J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of mTOR in tuberous sclerosis. Sampson JR Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. Mi R; Ma J; Zhang D; Li L; Zhang H J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245 [TBL] [Abstract][Full Text] [Related]
13. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Bonnet CS; Aldred M; von Ruhland C; Harris R; Sandford R; Cheadle JP Hum Mol Genet; 2009 Jun; 18(12):2166-76. PubMed ID: 19321600 [TBL] [Abstract][Full Text] [Related]
14. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Franz DN Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571 [TBL] [Abstract][Full Text] [Related]
16. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Cambiaghi M; Cursi M; Magri L; Castoldi V; Comi G; Minicucci F; Galli R; Leocani L Neuropharmacology; 2013 Apr; 67():1-7. PubMed ID: 23159330 [TBL] [Abstract][Full Text] [Related]
17. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Geoerger B; Kerr K; Tang CB; Fung KM; Powell B; Sutton LN; Phillips PC; Janss AJ Cancer Res; 2001 Feb; 61(4):1527-32. PubMed ID: 11245461 [TBL] [Abstract][Full Text] [Related]
19. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. MacKeigan JP; Krueger DA Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591 [TBL] [Abstract][Full Text] [Related]
20. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Wilson C; Idziaszczyk S; Parry L; Guy C; Griffiths DF; Lazda E; Bayne RA; Smith AJ; Sampson JR; Cheadle JP Hum Mol Genet; 2005 Jul; 14(13):1839-50. PubMed ID: 15888477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]